Department of Neurosurgery, West Virginia University, 1 Medical Center Drive, Morgantown, WV, 26506-9183, USA.
Department of Radiation Oncology, West Virginia University, Morgantown, WV, USA.
J Neurooncol. 2023 Sep;164(2):423-430. doi: 10.1007/s11060-023-04443-y. Epub 2023 Sep 5.
Intra-operative radiotherapy (IORT) for brain metastases (BMs) and primary brain tumors has emerged as an adjuvant radiation modality that allows for consolidation of care into a single anesthetic episode with surgical resection. Yet, there is a paucity of data regarding the impact that IORT may have on peri-operative and long-term seizure risk.
A retrospective analysis of patients receiving IORT during tumor resection was performed via registry including data regarding peri-operative anti-seizure medications and anesthetic agents. Intra-operative neuromonitoring was performed using electrocorticography (ECoG) captured before-, during-, and after-IORT then analyzed for evidence of seizure or significant baseline changes. Kaplan-Meir estimations were used for overall survival analysis relative to documented clinical seizure incidence post-IORT.
Of the 24 consecutive patients treated with IORT during tumor resection included, 18 (75%) patients were diagnosed with BMs while 6 (25%) had newly-diagnosed glioblastoma. Mean and median survival times were 487 and 372 days, respectively. Clinical seizures occurred in 3 patients post-IORT, 2 BMs patients within 9 months and 1 glioblastoma patient at 14 months. IORT time represented 9.5% of anesthetic time. ECoG recordings were available for 5 patients (4 BMs; 1 glioblastoma), with mean recording durations of 13% of the total anesthetic time and no evidence of high-frequency oscillations or seizure activity.
IORT is an option for delivery of definitive radiation in surgically resected brain tumors without increasing the peri-operative or long-term risk of seizure. ECoG data during the delivery of radiation fail to demonstrate any electrophysiological changes in response to ionizing radiation.
术中放疗(IORT)治疗脑转移瘤(BMs)和原发性脑肿瘤已成为一种辅助放疗方式,可将治疗整合到单次麻醉手术切除中。然而,关于 IORT 对围手术期和长期癫痫风险的影响的数据很少。
通过注册登记对接受肿瘤切除术中 IORT 的患者进行回顾性分析,包括围手术期抗癫痫药物和麻醉药物的数据。术中神经监测使用皮质电图(ECoG)进行,在 IORT 前后进行记录,然后分析是否有癫痫发作或明显的基线变化。Kaplan-Meier 估计用于相对于术后记录的临床癫痫发作的总生存分析。
在 24 例接受肿瘤切除术中 IORT 的连续患者中,18 例(75%)患者诊断为 BMs,6 例(25%)患者为新诊断的胶质母细胞瘤。平均和中位生存时间分别为 487 天和 372 天。术后发生 3 例临床癫痫发作,2 例 BMs 患者在 9 个月内,1 例胶质母细胞瘤患者在 14 个月内。IORT 时间占麻醉时间的 9.5%。有 5 例患者(4 例 BMs;1 例胶质母细胞瘤)可获得 ECoG 记录,平均记录时间占总麻醉时间的 13%,没有高频振荡或癫痫活动的证据。
IORT 是在手术切除的脑肿瘤中提供确定性放疗的一种选择,不会增加围手术期或长期癫痫风险。在放射治疗过程中 ECoG 数据未能显示任何电生理变化以应对电离辐射。